O-1602
跳至導覽
跳至搜尋
| File:O-1602.svg | |
| 識別資訊 | |
|---|---|
| |
| CAS號 | 317321-41-8 |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| E編碼 | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Module:EditAtWikidata第29行Lua錯誤:attempt to index field 'wikibase' (a nil value) |
| 化學資訊 | |
| 化學式 | C17H22O2 |
| 摩爾質量 | 258.36 g·mol−1 |
| 3D模型(JSmol) | |
| |
| |
O-1602是一種含氮有機化合物,化學式C
17H
22O
2,屬於一種大麻素,由美國Organix Inc公司開發,化學結構上與異常大麻二酚(Abn-CBD)相似,而和經典的大麻素受體CB1和CB2無明顯的成鍵傾向[1][2][3]。
參考文獻[編輯]
- ^ Ashton JC. The atypical cannabinoid O-1602: targets, actions, and the central nervous system. Central Nervous System Agents in Medicinal Chemistry. September 2012, 12 (3): 233–9. PMID 22831390. doi:10.2174/187152412802430156.
- ^ Schuelert N, McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neuroscience Letters. August 2011, 500 (1): 72–6. PMID 21683763. S2CID 3410391. doi:10.1016/j.neulet.2011.06.004.
- ^ Schicho R, Bashashati M, Bawa M, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflammatory Bowel Diseases. August 2011, 17 (8): 1651–64. PMC 3116968 可免費查閱. PMID 21744421. doi:10.1002/ibd.21538.